Drug Development in Oncology - 1st edition

The objective of this course is to give an overview on the development of drugs in oncology. 

It will focus on the preclinical and clinical phases of drug development, including the design and methodology of clinical trials, as well as precision medicine trials and thevalue of implementation of molecular tumor boards.

Clinical development of all anti-cancer drugs, including chemotherapy, targeted therapies and immunotherapy will be covered. Regulatory and economic aspects will also be discussed. 

To view the program please click here

SPEAKERS

BAYLE Arnaud - FR
BOGAERTS Jan - BE
BORCOMAN Edith - FR
BRAÑA Irene - ES
CALLENS Céline - FR
CLARK Anderson - US
FERNANDEZ Xosé - FR
HOUOT Roch - FR
KAMAL Maud - FR
LE TOURNEAU Christophe - FR
MAZARELLA Luca - IT
PAOLETTI Xavier - FR
PEREZ Franck - FR
PROVOST Claire - FR
RATAIN Mark - US
REZAI Keyvan - FR
SERVANT Nicolas - FR
STATHIS Anastasios - CH
VERHEUL Henk - NL
VON DER LEYEN Heiko - DE

OBJECTIVES

Strategy of preclinical development

From basic to clinical research

Preclinical development and animal models

Molecular screening

Methodology of clinical trials and judgment criteria (Phase I, II and III)

Evaluation of response to treatment

Design of dose finding studies

Toxicity assessment

Pharmacokinetics & Radiopharmacology 

Precision medicine in oncology

Precision medicine clinical trials

Molecular tumor boards and screening programs

Identification of biomarkers in oncology

Bioinformatics and data integration

Processing algorithms and standard of proof

Therapeutic strategies

Chemotherapy, radiotherapy, targeted therapies and immunotherapy

New therapeutic strategies (including Nanoparticles and CarT cells )

Regulatory aspects of clinical trials

Data management and exploitation

Economic models